Pharma China, the most influential English media and business intelligence service covering China's pharmaceutical sector, is pleased to announce the addition of Dr. Yan Yan L Starkey to its Advisory Board which is now consisted of 12 distinguished industry veterans. She will advise Pharma China editors in areas including clinical research, medical affairs and registration of Rx, OTC and consumer healthcare products in China and globally.

Dr. Yan Yan L Starkey has 16 years of experience in medical affairs, clinical research, regulatory affairs and project management for both OTC and Rx drugs, covering all phases of clinical trials in Pain/CNS, Cardiovascular, Urology, RT, GI and Oncology and registration programs in China and globally. Yan Yan also has extensive experience in supporting global R&D programs in BRIC markets especially China and India.

She is now Director of Medical Affairs for GlaxoSmithKline Consumer Healthcare based in New Jersey. Before joining GSK in 2007, Yan Yan worked with many multinational pharmaceutical companies including Novartis, Schering Plough and Yamanouchi in China and the U.S. with growing responsibilities in medical, regulatory and project management areas.

Most recently, she has authored a chapter entitled "China's Regulated Pharmaceutical Market" in "Principles and Practice of Pharmaceutical Medicine" which was published by Wiley in 2010.

Yan Yan has a MD degree from the No.4 Military Medical University in China, an MS in child neurology from the Peking Union Medical College and an MBA from the University Illinois at Chicago. Prior to joining the pharmaceutical industry, she practiced as a pediatrician in China for six years at Peking Union Medical College Hospital (A Rockefeller Foundation Hospital) and Beijing General Hospital.